Fly News Breaks for November 27, 2019
Nov 27, 2019 | 08:32 EDT
Cowen analyst Yaron Werber noted Ultragenyx shares have been weak due to concerns about the likelihood for success for DTX401 in GSD1a and its Q3 miss on global Crysvita sales. also leading to investor concerns was the announcement of its COO resignation. The analyst believes the change in protocol with DTX401 should boost its chance for success and recent weakness in Crysvita sales in Germany due to pricing should normalize. Werber reiterated his Outperform rating and $62 price target on Ultragenyx shares.
News For RARE From the Last 2 Days
There are no results for your query RARE